BC-1215 – 5 mg

Brand:
Cayman
CAS:
1507370-20-8
Storage:
-20
UN-No:
Non-Hazardous - /

BC-1215 is an inhibitor of F-box protein 3 (FBXO3; IC50 = 0.9 μg/mL for Il-1β release).{38454} It decreases FBXO3 interaction with F-box/LRR-repeat protein 2 (FBXL2) in a dose-dependent manner and prevents FBXO3-dependent ubiquitination of FBXL2. It also lowers expression of Tnf receptor-associated factors (TRAFs) 1-6 without affecting TRAF1-6 mRNA levels in resting and LPS-stimulated peripheral blood mononuclear cells (PBMCs). BC-1215 (100 μg, i.p., per animal) reduces plasma levels of the inflammatory cytokines Il-6, Tnf, and Il-1β and decreases peritoneal bacteria counts in a mouse model of cecal ligation and puncture-induced sepsis. It also reduces inflammation in mouse models of DSS-induced colitis, paw edema, and ear edema.{38455}  

 

Out of stock

SKU: 21964 - Category:

Description

An inhibitor of FBXO3 (IC50 = 0.9 μg/mL for Il-1β release); decreases FBXO3-FBXL2 interaction in a dose-dependent manner and prevents FBXO3-dependent ubiquitination of FBXL2; lowers expression of TRAF1-6 without affecting TRAF1-6 mRNA levels in resting and LPS-stimulated PBMCs; reduces plasma levels of the inflammatory cytokines Il-6, Tnf, and Il-1β and decreases peritoneal bacteria counts in a mouse model of cecal ligation and puncture-induced sepsis when administered at a dose of 100 μg, i.p., per animal; reduces inflammation in mouse models of DSS-induced colitis, paw edema, and ear edema,


Formal name: N1,N2-bis[[4-(2-pyridinyl)phenyl]methyl]-1,2-ethanediamine

Synonyms: 

Molecular weight: 394.5

CAS: 1507370-20-8

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Ubiquitin Ligase System||Research Area|Immunology & Inflammation|Gastric Disease|Ulcerative Colitis||Research Area|Immunology & Inflammation|Innate Immunity|Sepsis/Shock